Generation Bio Co
NASDAQ:GBIO

Watchlist Manager
Generation Bio Co Logo
Generation Bio Co
NASDAQ:GBIO
Watchlist
Price: 1.4 USD 2.19% Market Closed
Market Cap: 93.5m USD
Have any thoughts about
Generation Bio Co?
Write Note

Operating Margin
Generation Bio Co

-525.5%
Current
-1 915%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-525.5%
=
Operating Profit
-97.7m
/
Revenue
18.6m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Generation Bio Co
NASDAQ:GBIO
93.5m USD
-526%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
320.1B USD
28%
US
Amgen Inc
NASDAQ:AMGN
147.4B USD
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
40%
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
135.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.3B EUR
-22%
Country US
Market Cap 93.5m USD
Operating Margin
-526%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 320.1B USD
Operating Margin
28%
Country US
Market Cap 147.4B USD
Operating Margin
19%
Country US
Market Cap 119.4B USD
Operating Margin
40%
Country US
Market Cap 113.8B USD
Operating Margin
38%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 135.4B AUD
Operating Margin
26%
Country US
Market Cap 82.6B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 34.3B EUR
Operating Margin
-22%
No Stocks Found

Generation Bio Co
Glance View

Market Cap
93.5m USD
Industry
Biotechnology

Generation Bio Co. is a genetic medicine company focused on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 150 full-time employees. The company went IPO on 2020-06-12. The firm through its non-viral genetic medicine platform, is engaged in developing genetic medicines to provide genetic payloads, which include large and multiple genes to a range of cell types across a range of diseases. The company is comprised of three component technologies: ceDNA, ctLNP and ceDNA manufacturing process. ceDNA is an engineered, double-stranded, linear, covalently closed-ended deoxyribonucleic acid (DNA) construct, which includes the gene of interest and associated regulatory sequences. The company has produced ceDNA constructs of approximately eight kilobases. Its ctLNP delivery system builds upon clinically validated lipid nanoparticles and is designed to allow for repeat dosing of a genetic payload without stimulating an immune response, such as antibody production. Its ceDNA manufacturing process uses its own cell-free rapid enzymatic synthesis (RES) to produce ceDNA.

GBIO Intrinsic Value
1.09 USD
Overvaluation 22%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-525.5%
=
Operating Profit
-97.7m
/
Revenue
18.6m
What is the Operating Margin of Generation Bio Co?

Based on Generation Bio Co's most recent financial statements, the company has Operating Margin of -525.5%.